Prediction of Drug Interactions With CYP2C9 Substrates
Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.
Sponsor: Hadassah Medical Organization
Listed as NCT00226538, this NA trial focuses on Healthy Volunteers and remains completed. Sponsored by Hadassah Medical Organization, it has been updated 5 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Aug 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hadassah Medical Organization
For direct contact, visit the study record on ClinicalTrials.gov .